| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Sinomenine (Coculine; Cucoline; Kukoline) is a naturally occuring alkaloid found in the root of the climbing plant Sinomenium acutum which is native to Japan and China. It is traditionally used in herbal medicine in these countries, as a treatment for rheumatism and arthritis. However, its analgesic action against other kinds of pain is limited. Sinomenine is a morphinan derivative, related to opioids such as levorphanol and the non-opioid cough suppressant dextromethorphan.
| ln Vitro |
Tanshinone IIA has anti-tumor properties such as increasing tumor cell death, decreasing short-term cell proliferation, altering the tumor cell cycle, and so on. Tanshinone IIA demonstrates anti-tumor actions on A549 cells; at 24, 48, and 72 hours, the IC50 of tanshinone IIA was 145.3, 30.95, and 11.49 μM, respectively. The proliferative activity of A549 cells treated with tanshinone IIA (2.5 - 80 μM) for 24, 48, and 72 hours, respectively, was assessed using the CCK-8 assay. The CCK-8 results shown that tanshinone IIA may, in a dose- and time-inhibitory manner, strongly suppress the growth of A549 cells. After 48 days of medication therapy, significant reduction of A549 cell growth and concentration was detected (concentration trace IC50 values used: Tanshinone IIA 31 μM vs. A549). Using Western blotting, it was discovered that both drug-treated groups expressed VEGF and VEGFR2 48 hours after subjecting A549 cells to tanshinone IIA (31 μM) as opposed to the vehicle [1]. The most prevalent ingredient in Salvia miltiorrhiza root is tanshinone IIA. Tanshinone IIA H9C2 cells express transcribed PTEN (phosphatase and tensin homolog), a protein that functions in cells, which causes angiotensin II-induced cellular fluorescence. important impediment. By phosphorylating phosphatase and tensin homolog (PTEN) expression, tanshinone IIA suppresses cytokines that are produced by angiotensin II (AngII) [2]. Tanshinone IIA promotes PI3K/Akt/mTOR luster and decreases the expression of the EGFR and IGFR proteins in AGS cells [3].
|
|---|---|
| ln Vivo |
The cognitive impairment caused by scopolamine is significantly reversed by tanshinone IIA (10 or 20 mg/kg; sidewall) [4]. By blocking PERK signaling, tanshinone IIA (2, 4, 8 mg/kg; i.p.) may reduce endoplasmic reticulum daytime, which may be linked to the mediated protective effect on STZ-induced diabetic nephropathy [5]. Ectopic protein intima development is markedly inhibited by tanshinone IIA (3 and 12 mg/kg; ip) [6].
|
| Animal Protocol |
Animal/Disease Models: Male ICR mice (25–30 g)[4]
Doses: 10 or 20 mg/kg Route of Administration: Oral Experimental Results:Dramatically reversed scopolamine-induced cognitive impairment. Animal/Disease Models: STZ-treated rats [5] Doses: 2, 4, 8 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: diminished expression levels of transforming growth factor-β1, TSP-1, Grp78 and CHOP, and attenuated protein increased the levels of p-PERK, p-elf2α and ATF-4 in the renal tissue of diabetic rats. Animal/Disease Models: Female SD (SD (Sprague-Dawley)) rats (180 -200g) [6] Doses: 3 and 12 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Dramatically inhibited the growth of ectopic endometrium. |
| References |
[1]. Xie J, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B. 2015 Nov;5(6):554-63.
[2]. Zhang Z, et al. Tanshinone IIA inhibits apoptosis in the myocardium by inducing microRNA-152-3p expression and thereby downregulating PTEN. Am J Transl Res. 2016 Jul 15;8(7):3124-32. [3]. Su CC, et al. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep. 2016 Aug;36(2):1173-9. |
| Molecular Formula |
C19H18O3
|
|
|---|---|---|
| Molecular Weight |
294.34
|
|
| CAS # |
568-72-9
|
|
| Related CAS # |
|
|
| SMILES |
CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C
|
|
| InChi Key |
INYYVPJSBIVGPH-WTOJCKNJSA-N
|
|
| InChi Code |
InChI=1S/C19H23NO4/c1-20-7-6-19-10-14(21)16(24-3)9-12(19)13(20)8-11-4-5-15(23-2)18(22)17(11)19/h4-5,9,12-13,22H,6-8,10H2,1-3H3/t12-,13-,19+/m0/s1
|
|
| Chemical Name |
(9alpha,13alpha,14alpha)-7,8-Didehydro-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3974 mL | 16.9872 mL | 33.9743 mL | |
| 5 mM | 0.6795 mL | 3.3974 mL | 6.7949 mL | |
| 10 mM | 0.3397 mL | 1.6987 mL | 3.3974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA